What changed in Qiagen N.V.'s latest annual report
In the year ended 31 Dec 2025, Qiagen N.V.'s revenue rose 5.7% to USD 2.09bn, from USD 1.98bn; net income rose 408.3% to USD 424.88m, from USD 83.59m; long-term debt rose 97% to USD 1.65bn, from USD 839.66m.
Year ended 31 Dec 2025. Source: 20-F filed 20 Mar 2026, read it on SEC EDGAR.
USD 1.98bn to USD 2.09bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 1.98bn | 2.09bn | Up 5.7% |
| Net income | 83.59m | 424.88m | Up 408.3% |
| Total assets | 5.69bn | 6.28bn | Up 10.4% |
| Long-term debt | 839.66m | 1.65bn | Up 97% |
| Cash and cash equivalents | 663.55m | 839.00m | Up 26.4% |
| Shareholders' equity | 3.57bn | 3.78bn | Up 5.9% |
Questions people ask
Did Qiagen N.V.'s revenue grow last year?
Revenue grew 5.7%, from USD 1.98bn to USD 2.09bn in the year ended 31 Dec 2025.
Is Qiagen N.V. profitable?
Yes. Net income was USD 424.88m in the year ended 31 Dec 2025. The year before: USD 83.59m.
How much cash and debt does Qiagen N.V. have?
At its latest year end (31 Dec 2025), Qiagen N.V. reported cash and cash equivalents of USD 839.00m and long-term debt of USD 1.65bn.
Where do these numbers come from?
From Qiagen N.V.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Qiagen N.V.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%